Evaluating sativex® in neuropathic pain management: A clinical and neurophysiological assessment in multiple sclerosis

Pain Medicine (United States)

Volumn 17, Issue 6, 2016, Pages 1145-1154

  Russo, Margherita ^a   Naro, Antonino ^a   Leo, Antonino ^a   Sessa, Edoardo ^a   D’Aleo, Giangaetano ^a   Bramanti, Placido ^a   Calabrò, Rocco Salvatore ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Central neuropathic pain; Laser evoked potentials; Multiple sclerosis; Sativex; TMS

Indexed keywords

NABIXIMOLS; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAMMA RHYTHM; HUMAN; LASER EVOKED POTENTIAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; PAIN ASSESSMENT; QUALITY OF LIFE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; BRAIN; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; NEURALGIA; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; BRAIN; FEMALE; HUMANS; LASER-EVOKED POTENTIALS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEURALGIA; PAIN MANAGEMENT; PAIN MEASUREMENT; PLANT EXTRACTS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 85010905685     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1093/pm/pnv080     Document Type: Article

References (50)

1. Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008; 22: 291–324.
2. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630–5.
3. Zajicek JP, Ingram WM, Vickery J, et al. Patient orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: Protocol and baseline characteristics of cohort. BMC Neurol 2010; 10: 88.
4. Solaro C. Epidemiology and treatment of pain in multiple sclerosis subjects. Neurol Sci 2006 Sep; 27 (suppl 4): s291–3.
5. Iskedjian M, Brezza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007; 23: 17–24.
6. Perez J, Ribera MV. Managing neuropathic pain with Sativex: A review of its pros and cons. Expert Opin Pharmacother 2008; 9: 1189–95.
7. Meuth SG, Vila C, Dechant KL. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother 2015; 15: 909–18.
8. Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234–46.
9. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol 2000; 5: 37–44.
10. Wright S. Cannabinoid-based medicines for neurological disorders–clinical evidence. Mol Neurobiol 2007 Aug; 36 (1): 129–36.
11. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex VR), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122–31.
12. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013; 260: 984–97.
13. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebocontrolled clinical trial. Pain 2007; 133: 210–20.
14. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 29: 2068–79.
15. Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain 2006; 122: 289–99.
16. Treede RD, Lorenz J, Baumgä rtner U. Clinical usefulness of laser-evoked potentials. Neurophysiol Clin 2003; 33: 303–14.
17. Garcia-Larrea L, Convers P, Magnin M, et al. Laserevoked potential abnormalities in central pain patients: The influence of spontaneous and provoked pain. Brain 2002; 125: 2766–81.
18. Valeriani M, Pazzaglia C, Cruccu G, Truini A. Clinical usefulness of laser evoked potentials. Neurophysiol Clin 2012; 42: 345–53.
19. Mouraux A, Iannetti GD. Nociceptive laser-evoked brain potentials do not reflect nociceptive-specific neural activity. J Neurophysiol 2009; 101: 3258–69.
20. Zhang ZG, Hu L, Hung YS, Mouraux A, Iannetti GD. Gamma-band oscillations in the primary somatosensory cortex–a direct and obligatory correlate of subjective pain intensity. J Neurosci 2012; 32 (22): 7429–38.
21. Gross J, Schnitzler A, Timmermann L, Ploner M. Gamma oscillations in human primary somatosensory cortex reflect pain perception. PLoS Biol 2007; 5: e133.
22. Valeriani M, Restuccia D, Di Lazzaro V, et al. Inhibition of the human primary motor area by painful heat stimulation of the skin. Clin Neurophysiol 1999; 110: 1475–80.
23. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114 (1-2): 29–36.
24. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald Criteria’’. Ann Neurol 2005; 58: 840–6.
25. Polman CH1, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
26. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain. Arthritis Care Res 2011; 63 (S11): S240–52.
27. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 Numeric Rating Scale Measure of Spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974–85.
28. Bohannon R, Smith M. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206.
29. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187–206.
30. Rossini PM, Barker AT, Berardelli A, et al. Noninvasive electrical and magnetic stimulation of the brain, spinal cord and roots: Basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr. Clin Neurophysiol 1994; 91: 79–92.
31. Iannetti GD, Hughes NP, Lee MC, Mouraux A. Determinants of laser-evoked EEG responses: Pain perception or stimulus saliency? J Neurophysiol 2008; 100: 815–28.
32. Naro A, Leo A, Russo M, et al. Shaping thalamocortical plasticity: A marker of cortical pain integration in patients with post-anoxic unresponsive wakefulness syndrome? Brain Stimul 2014; 8: 97-104.
33. Arendt-Nielsen L, Brennum J, Sindrup S, Bak P. Electrophysiological and psychophysical quantification of temporal summation in the human nociceptive system. Eur J Appl Physiol Occup Physiol 1994; 68: 266–73.
34. Sandrini G, Arrigo A, Bono G, Nappi G. The nociceptive flexion reflex as a tool for exploring pain control systems in headache and other pain syndromes. Cephalalgia 1993; 13: 21–7.
35. Hu L, Cai MM, Xiao P, Luo F, Iannetti GD. Human brain responses to concomitant stimulation of Ad and C nociceptors. J Neurosci 2014 20; 34: 11439–51.
36. Delorme A, Makeig S. EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 2004; 134: 9–21.
37. Pfurtscheller G, Lopes da Silva FH. Event-related EEG/MEG synchronization and desynchronization: Basic principles. Clin Neurophysiol 1999; 110: 1842–57.
38. Merskey HBN. Classification of Chronic Pain: Description of Chronic Pain Syndromes and Definitions of Pain Terms. Seattle, WA: IASP Press; 1994.
39. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis–prevalence and clinical characteristics. Eur J Pain 2005; 9: 531–42.
40. Svendsen KB1, Sørensen L, Jensen TS, Hansen HJ, Bach FW. MRI of the central nervous system in MS patients with and without pain. Eur J Pain 2011; 15: 395–401.
41. Kelly S, Chapman V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 2001; 86: 3061–4.
42. Costa B. On the pharmacological properties of delta-9-tetrahydrocannabinol (THC). Chem Biodivers 2007; 4: 1664.
43. Xiong W, Cui T, Cheng K, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors. J Exp Med 2012; 209: 1121–34.
44. Ohara PT, Vit JP, Jasmin L. Cortical modulation of pain. Cell Mol Life Sci 2005; 62: 44–52.
45. Treede RD, Kenshalo DR, Gracely RH, Jones AK. The cortical representation of pain. Pain 1999; 79: 105–11.
46. Franca NR, Toniolo EF, Franciosi AC, et al. Antinociception induced by motor cortex stimulation: Somatotopy of behavioral response and profile of neuronal activation. Behav Brain Res 2013; 250: 211–21.
47. Centonze D, Mori F, Koch G, et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009; 30: 531–4.
48. Truini A, Galeotti F, La Cesa S, et al. Mechanisms of pain in multiple sclerosis: A combined clinical and neurophysiological study. Pain 2012; 153: 2048–54.
49. Costa B, Trovato AE, Colleoni M, et al. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005; 116: 52–61.
50. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: A maladaptive response of the nervous system to damage. Ann Rev Neurosci 2009; 32: 1–32.